Surface Oncology Continues Gains, Up 45%; In Clinical Trial Collaboration with Merck
May 21 2020 - 10:47AM
Dow Jones News
By Michael Dabaie
Surface Oncology shares continued the previous day's gains in
Thursday morning trading, recently up 45% to $5.61.
Surface Wednesday said it entered into a clinical trial
collaboration with Merck & Co., through a subsidiary, to
evaluate combining Surface's SRF617 with Merck's Keytruda.
The combination will be studied as a component of a Phase 1/1b
study of SRF617 and will be evaluated in patients with solid
tumors, with a focus on patients with gastric cancer and those who
have developed resistance to checkpoint inhibition, areas of high
unmet need, Surface said.
Surface also said Wednesday that it raised gross proceeds of
about $28.9 million through its at-the-market facility.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
May 21, 2020 10:32 ET (14:32 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2023 to Apr 2024
